About Senticell
Senticell is a pioneering biotechnology and molecular diagnostics company developing a breakthrough platform that uses red blood cell (RBC) DNA and cfDNA analysis to revolutionize non-invasive disease detection.
Our research demonstrates that RBCs act as immune-responsive biosensors, capable of carrying molecular and genetic biomarkers from across the body - unlocking a powerful and previously untapped gateway for liquid biopsy and precision diagnostics.
By harnessing this cellular intelligence, we enable early disease detection, biomarker discovery and AI-driven diagnostic insights to support precision medicine and personalised treatment outcomes.
Founded on groundbreaking research at the University of Pennsylvania, Senticell is led by Dr. Nilam Mangalmurti, a distinguished physician-scientist and a multidisciplinary team of immunologists, molecular biologists, and bioengineers.
Our proprietary red blood cell (RBC) diagnostic platform enables the detection of disease-specific RNA, cfDNA and protein biomarkers from a simple blood sample providing a non-invasive, rapid and highly scalable molecular diagnostics solution.
Bridging academic discovery and clinical translation, Senticell is pioneering a new class of RBC-based liquid biopsy technologies designed to detect disease at the molecular level. By transforming the most abundant human blood cell into an intelligent biosensor, we are shaping the future of precision medicine, early detection and personalized healthcare innovation.
